All Stories

  1. UMOD Genotype and Clinical Outcomes in Heart Failure Patients Treated with Loop Diuretics: A UK Biobank Pharmacogenetic...
  2. Direct Oral Anticoagulants, COX-2–Selective NSAIDs, and Gastrointestinal Bleeding in Atrial Fibrillation
  3. Validation of an AI-Assisted Framework for Systematic Bias Assessment in Observational Studies
  4. Re‐evaluation of sucralose (E 955) as a food additive and evaluation of a new application on extension of use of sucralose (E 955) in fine bakery wares
  5. Influenza Immunization at Midlife and the Risk of Parkinson Disease
  6. Use of fluoroquinolones and the risk of seizures: a population-based cohort study
  7. Comparative effectiveness and safety of oral anticoagulants in patients with atrial fibrillation using antiarrhythmic drugs: An international cohort study
  8. A disproportionality analysis on proprotein convertase subtilisin/kexin type 9 inhibitors and hypersensitivity and anaphylaxis
  9. Sodium glucose co‐transporter 2 inhibitors versus dipeptidyl peptidase‐4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population‐based cohort study
  10. Concomitant use of direct oral anticoagulants and interacting antiarrhythmic drugs and the risk of stroke and bleeding among patients with non-valvular atrial fibrillation: a multinational cohort study
  11. Serum uric acid and the risk of major adverse cardiovascular events and death among older adults: a population-based prospective cohort study
  12. Invited Commentary: Building rigorous clinical evidence for drug-drug interactions
  13. Ibuprofen gegen alles?
  14. Effectiveness and safety of concomitant use of direct oral anticoagulants and antiarrhythmic drugs: a systematic review of observational studies
  15. The Risk of Bleeding in Pregnant Women with Acute Venous Thromboembolism Treated with Anticoagulants: An International Multi-Database Cohort Study
  16. Advancing Health Equity in Europe: Explore, Tailor, Implement, and Evaluate (ETIE)—A Framework of Diversity and Fairness in Pharmacoepidemiologic Research
  17. CTRH as Biomarker of Drug Efficacy: In-Depth Assessment of Real-World Evidence
  18. Safety of concomitant use of oral anticoagulants and antidiabetic drugs: a systematic review of observational studies
  19. Evaluation of Drug–Drug Interactions in Pharmacoepidemiologic Research
  20. Masking in Active Comparator Designs in Pharmacovigilance: A Retrospective Bias Analysis on the Spontaneous Reporting of Thiazolidinediones and Cardiovascular Events
  21. Handbook of Epidemiology
  22. The Prevalent New‐User Design to Study Drug–Drug Interactions: The Example of Sulfonylureas and Warfarin Interaction on the Risk of Severe Hypoglycemia
  23. Comparative risk of infection of medications used for type 2 diabetes
  24. Masking in Active Comparator Designs in Pharmacovigilance: A Retrospective Bias Analysis on the Spontaneous Reporting of Thiazolidinediones and Cardiovascular Events
  25. Opioid Use and the Risk of Ventricular Arrhythmias: A Systematic Review and Meta‐Analysis
  26. Comparators in Pharmacovigilance: A Quasi-Quantification Bias Analysis
  27. Fluoroquinolones and the risk of severe hypoglycaemia among sulphonylurea users: Population‐based cohort study
  28. Methodological Considerations on the Use of Cohort Designs in Drug-Drug Interaction Studies in Pharmacoepidemiology
  29. Effectiveness and safety of direct oral anticoagulants among patients with non-valvular atrial fibrillation and liver disease: A multinational cohort study
  30. Infectious Disease Burden and the Risk of Alzheimer’s Disease: A Population-Based Study
  31. Diagnostic Validity of Chronic Kidney Disease in Health Claims Data Over Time: Results from a Cohort of Community-Dwelling Older Adults in Germany
  32. Clinically apparent Helicobacter pylori infection and the risk of incident Alzheimer's disease: A population‐based nested case‐control study
  33. Incretin‐based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: A systematic review and meta‐analysis of observational studies
  34. Kidney function estimators for drug dose adjustment of direct oral anticoagulants in older adults with atrial fibrillation
  35. Risk of opioid-related mortality associated with buprenorphine versus methadone: A systematic review of observational studies
  36. Pharmacologic heterogeneity and risk of severe hypoglycemia with concomitant use of sulfonylureas and DPP‐4 inhibitors: population‐based cohort study
  37. Kidney Measures and Risk of Incident Heart Failure Among Older Adults
  38. Considerations on the use of different comparators in pharmacovigilance: a methodological review
  39. Use of a Statistical Adaptive Treatment Strategy Approach for Emulating Randomized Controlled Trials Using Observational Data: The Example of Blood Pressure Control Strategies for the Prevention of Cardiovascular Events Among Individuals with Hypertens...
  40. Concomitant use of statins and sodium‐glucose co‐transporter 2 inhibitors and the risk of myotoxicity reporting ‐ A disproportionality analysis
  41. Sulfonylureas versus metformin and the risk of ventricular arrhythmias among people with type 2 diabetes: a population‐based cohort study
  42. Adherence and Quality of Life in Non-Valvular Atrial Fibrillation With Direct Oral Anticoagulants Versus Vitamin K Antagonists: A Systematic Review
  43. Common vaccines and the risk of incident dementia: a population-based cohort study
  44. Concomitant Use of Sulfonylureas and β-Blockers and the Risk of Severe Hypoglycemia Among Patients With Type 2 Diabetes: A Population-Based Cohort Study
  45. Challenges in evaluating treatments for COVID-19: The case of in-hospital anticoagulant use and the risk of adverse outcomes
  46. Effectiveness and safety of direct oral anticoagulants among octogenarians with venous thromboembolism: an international multi-database cohort study
  47. Obesity as a modifier of the Cardiovascular effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes
  48. Concomitant Use of Sulfonylureas and Warfarin and the Risk of Severe Hypoglycemia: Population-Based Cohort Study
  49. Bleeding in women with venous thromboembolism during pregnancy: A systematic review of the literature
  50. Response to: Real‐World Data on the Risk of Ventricular Arrhythmias with Sulfonamides
  51. Investigating Potential Drug-Drug Interactions from Greek e-Prescription Data
  52. Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials
  53. 5‐Alpha Reductase Inhibitors and the Risk of Anemia among Men with Benign Prostatic Hyperplasia: A Population‐based Cohort Study
  54. Sulfonylureas and the Risk of Ventricular Arrhythmias Among People with Type 2 Diabetes: A Systematic Review of Observational Studies
  55. Effectiveness and safety of direct oral anticoagulants with antiplatelet agents in patients with venous thromboembolism: A multi‐database cohort study
  56. Pharmacoepidemiology
  57. Prescription Patterns for the Use of Antihypertensive Drugs for Primary Prevention among Patients with Hypertension in the United Kingdom
  58. Utilization and long‐term persistence of direct oral anticoagulants among patients with non‐valvular atrial fibrillation and liver disease
  59. Validity of an algorithm to identify cardiovascular deaths from administrative health records: a multi-database population-based cohort study
  60. The Modifying Effects of Adiposity on the Cardiovascular Safety of Sulfonylureas
  61. Infectious Disease Burden and the Risk of Alzheimer’s Disease: A Population-Based Study
  62. Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: pharmacological and clinical evidence
  63. Global COVID ‐19 Pandemic and Reporting Behavior ‐ An Analysis of the Food and Drug Administration Adverse Events Reporting System ( FAERS )
  64. Effectiveness and safety of direct oral anticoagulants in patients with cancer associated venous thromboembolism
  65. Domperidone and the Risks of Sudden Cardiac Death and Ventricular Arrhythmia: A Systematic Review and Meta‐Analysis of Observational Studies
  66. Tyrosine kinase inhibitors targeting vascular endothelial growth factor and the risk of aortic dissection—A pharmacovigilance analysis
  67. Control of blood pressure in older patients with heart failure and the risk of mortality: a population-based prospective cohort study
  68. Sodium-glucose co-transporter 2 inhibitors and the risk of venous thromboembolism in patients with type 2 diabetes: a cohort study
  69. Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study
  70. Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study
  71. Author response: Degree of serotonin reuptake inhibition of antidepressants and ischemic risk: A cohort study
  72. Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis
  73. Sodium‐glucose Cotransporter 2 Inhibitors and the Risk for Urosepsis – A Multi‐site Prevalent New‐user Cohort Study
  74. Direct oral anticoagulants and oesophageal disorders: a pharmacovigilance analysis
  75. Self-reported medication in community-dwelling older adults in Germany: results from the Berlin Initiative Study
  76. Comparative cardiovascular and hypoglycemic safety of glimepiride in type 2 diabetes: A population‐based cohort study
  77. Degree of serotonin reuptake inhibition of antidepressants and ischemic risk
  78. Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes
  79. Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Adverse Cardiovascular Events: A Population‐based Cohort Study
  80. Opioids and the Risk of Infection: A Critical Appraisal of the Pharmacologic and Clinical Evidence
  81. Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes
  82. Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis of Observational Studies
  83. Reviewing the effects of thiazide and thiazide-like diuretics as photosensitizing drugs on the risk of skin cancer
  84. RE: Metformin Use and Gastric Cancer Risk in Diabetic Patients After Helicobacter pylori Eradication
  85. Control of blood pressure and risk of mortality in a cohort of older adults: the Berlin Initiative Study
  86. What Fluoroquinolones Have the Highest Risk of Aortic Aneurysm? A Case/Non-case Study in VigiBase®
  87. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study
  88. Concomitant Use of Direct Oral Anticoagulants with Antiplatelet Agents and the Risk of Major Bleeding in Patients with Nonvalvular Atrial Fibrillation
  89. Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy
  90. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study
  91. Use of dipeptidyl peptidase-4 inhibitors and new-onset rheumatoid arthritis in patients with type 2 diabetes
  92. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study
  93. Risk of Intracranial Hemorrhage Associated with the Use of Antidepressants Inhibiting Serotonin Reuptake: A Systematic Review
  94. Non–Vitamin K Antagonist Oral Anticoagulants and Risk of Serious Liver Injury
  95. Single-Pill Triple Fixed Dose Combination Therapy with Single Component Drug Monitoring in Treatment-Resistant Hypertension: A Pilot Study
  96. Drug-induced kidney injury: A large case series from the Berlin Case-Control Surveillance Study

  97. Patterns of long-term use of non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation: Quebec observational study
  98. Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events
  99. Immobilization and high platelet count are associated with thromboembolic complications in heparin-induced thrombocytopenia
  100. Tocilizumab-induced pancreatitis: case report and review of data from the FDA Adverse Event Reporting System
  101. Risk of venous thromboembolism in cancer patients treated with epoetins or blood transfusions
  102. Pharmakovigilanz in Deutschland
  103. Herb-Induced Liver Injury in the Berlin Case-Control Surveillance Study
  104. Corrigendum
  105. Drug–drug interactions and safety of linezolid, tedizolid, and other oxazolidinones
  106. Drug-induced liver injury: results from the hospital-based Berlin Case-Control Surveillance Study
  107. Estimating kidney function and use of oral antidiabetic drugs in elderly
  108. Erratum to: Flupirtine-induced liver injury—Seven cases from the Berlin Case–control Surveillance Study and review of the German spontaneous adverse drug reaction reporting database
  109. Safety issues and drug–drug interactions with commonly used quinolones
  110. Insufficient anticoagulation with dabigatran in a patient with short bowel syndrome
  111. Flupirtine-induced liver injury—Seven cases from the Berlin Case–control Surveillance Study and review of the German spontaneous adverse drug reaction reporting database
  112. Drug-induced acute pancreatitis: results from the hospital-based Berlin case-control surveillance study of 102 cases
  113. Ramipril-Induced Liver Injury: Case Report and Review of the Literature